Genmab — December 2012
-
0557] Combinations of EGFR antibody LC1006-003 with 2F8-IgG1, 2F8-IgG4 or 2F8-F(ab)2 were tested in their ability to bind C1q and C4c, and to induce CDC. A431 cell line was used as target. It was found that relevant complement-deposition and -lysis was only observed in the presence of two human IgG1 Fc fragments (FIGS. 15 and 16).
-
-
vildt!
-
men det ser så faktisk ud som om de har afprøvet det med Zalu
-
Jeg har spurgt genmab om de har testet HexaBody på Zalutumumab
-
Det vil de ikke svare på
-
-
og her det gamle abstract der er kombi af to antibodies http://www.biomedexperts.com/Abstract.bme/21832160/Epidermal_growth_factor_receptor_EGFR_antibody-induced_antibody-dependent_cellular_cytotoxicity_plays_a_prominent_role
-
På GSK.com står Ofatumumab sc fase 2 i RA. http://www.gsk.com/investors/product-pipeline.html
Er det en fejl eller kører et sådant forsøg? Jeg kan ikke finde et på clinicaltrials.gov -
-
Men du linker til Multiple Sclerose forsøget, der ligger ikke et på Reumatoid Artrit.
-
På side 14 i vedlagte ses hexabodien, mener jeg at være kommet frem til http://www.dls.ym.edu.tw/imm/The Complement System-052506.pdf
-
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind